Toxicities related to immunotherapies approved for the treatment of patients with non–small-cell lung cancer (NSCLC) are uncommon but can be life-threatening.
It is now widely known that light cigarettes are no safer than regular cigarettes and were only marketed in an attempt to undermine smokers’ wishes to quit smoking. According to Charlotta Pisinger, PhD, MPH, the tobacco industry is now using the same tactic with electronic cigarettes (e-cigarettes).
Targeted agents and immunotherapy are displacing chemotherapy in certain subgroups of the treatment of lung cancer, but chemotherapy remains a key therapeutic pillar in the daily management of patients with this disease, according to Jean-Charles Soria, MD, PhD, Head of the Drug Development Department, Gustave Roussy, Villejuif, France.
The prevalence of malnutrition in patients with lung cancer is particularly high, but early and intensive individualized dietary counseling can improve quality of life for these patients and decrease their chances of experiencing significant weight loss.
If you cannot get your patients with lung cancer to stop smoking, at least encourage them to exercise.
Pemetrexed (Alimta) is a pyrrolopyrimidine-core folate analog metabolic inhibitor that disrupts the folate-dependent metabolic processes essential for cell replication. Pemetrexed exhibits its antineoplastic activity by inhibiting several key enzymes in the de novo synthesis of purine and pyrimidine nucleotides in neoplastic cells, resulting in cellular cytotoxicity.
Approval of First Liquid Biopsy to Detect EGFR Mutations in Lung Cancer Can Improve Patient Outcomes
The first liquid biopsy used to detect gene mutations that are associated with non–small-cell lung cancer (NSCLC) was approved by the US Food and Drug Administration (FDA).
Boston, MA–In a first-of-its-kind study, aprepitant (Emend), a centrally acting neurokinin (NK)-1 antagonist indicated for the treatment of chemotherapy-induced nausea and vomiting (CINV), led to a reduction in cough frequency and an improvement in the objective and subjective measures of cough in patients with lung cancer.
Boston, MA-What is the best chemotherapy regimen to use for patients with locally advanced nonsquamous non-small-cell lung cancer (NSCLC)? The phase 3 PROCLAIM trial attempted to answer this question, but the study failed to determine the best regimen for this patient population.
At the 16th Annual International Lung Cancer Congress, Tony Mok, MD, Professor of Clinical Oncology at the Chinese University of Hong Kong, provided an overview of the next generation of agents, taking stock of the recent past for insights into the future of drug discovery.
Page 1 of 5
Results 1 - 10 of 41
Results 1 - 10 of 41